News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
746,202 Results
Type
Article (44027)
Company Profile (313)
Press Release (701844)
Multimedia
Podcasts (121)
Webinars (22)
Section
Business (211066)
Career Advice (2110)
Deals (36777)
Drug Delivery (133)
Drug Development (83483)
Employer Resources (176)
FDA (16876)
Job Trends (15517)
News (357573)
Policy (34147)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2630)
Accelerated approval (42)
Adcomms (27)
Allergies (166)
Alliances (51589)
ALS (196)
Alzheimer's disease (1760)
Antibody-drug conjugate (ADC) (378)
Approvals (17188)
Artificial intelligence (615)
Autoimmune disease (225)
Automation (50)
Bankruptcy (374)
Best Places to Work (11769)
BIOSECURE Act (21)
Biosimilars (207)
Biotechnology (187)
Bladder cancer (177)
Brain cancer (67)
Breast cancer (694)
Cancer (5359)
Cardiovascular disease (458)
Career advice (1793)
Career pathing (39)
CAR-T (300)
CDC (56)
Celiac Disease (2)
Cell therapy (805)
Cervical cancer (41)
Clinical research (71784)
Collaboration (1936)
Company closure (4)
Compensation (1261)
Complete response letters (77)
COVID-19 (2797)
CRISPR (104)
C-suite (992)
Cystic fibrosis (152)
Data (7055)
Decentralized trials (3)
Denatured (37)
Depression (155)
Dermatology (57)
Diabetes (554)
Diagnostics (6907)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (299)
Drug pricing (210)
Drug shortages (32)
Duchenne muscular dystrophy (268)
Earnings (92769)
Editorial (62)
Employer branding (21)
Employer resources (155)
Events (121259)
Executive appointments (1054)
FDA (20308)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1618)
Gene editing (217)
Generative AI (53)
Gene therapy (670)
GLP-1 (1058)
Government (4835)
Grass and pollen (7)
Guidances (397)
Healthcare (19102)
HIV (73)
Huntington's disease (52)
IgA nephropathy (93)
Immunology and inflammation (281)
Immuno-oncology (81)
Indications (156)
Infectious disease (3110)
Inflammatory bowel disease (207)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (277)
Interviews (327)
IPO (16928)
IRA (57)
Job creations (4072)
Job search strategy (1499)
JPM (65)
Kidney cancer (18)
Labor market (92)
Layoffs (581)
Leadership (36)
Legal (8425)
Liver cancer (98)
Longevity (29)
Lung cancer (718)
Lymphoma (408)
Machine learning (53)
Management (60)
Manufacturing (934)
MASH (182)
Medical device (13939)
Medtech (14016)
Mergers & acquisitions (20997)
Metabolic disorders (1437)
mRNA (184)
Multiple sclerosis (172)
NASH (18)
Neurodegenerative disease (385)
Neuropsychiatric disorders (99)
Neuroscience (3170)
Neurotech (1)
NextGen: Class of 2026 (6647)
Non-profit (4572)
Now hiring (73)
Obesity (680)
Opinion (299)
Ovarian cancer (184)
Pain (244)
Pancreatic cancer (254)
Parkinson's disease (337)
Partnered (34)
Patents (557)
Patient recruitment (587)
Peanut (63)
People (61236)
Pharmaceutical (86)
Pharmacy benefit managers (33)
Phase 1 (22278)
Phase 2 (31573)
Phase 3 (23652)
Pipeline (7083)
Policy (318)
Postmarket research (2655)
Preclinical (9462)
Press Release (68)
Prostate cancer (276)
Psychedelics (51)
Radiopharmaceuticals (308)
Rare diseases (1016)
Real estate (6308)
Recruiting (72)
Regulatory (25834)
Reports (54)
Research institute (2454)
Resumes & cover letters (362)
Rett syndrome (32)
RNA editing (18)
RSV (85)
Schizophrenia (169)
Series A (272)
Series B (201)
Service/supplier (11)
Sickle cell disease (109)
Special edition (25)
Spinal muscular atrophy (167)
Sponsored (46)
Startups (3775)
State (2)
Stomach cancer (19)
Supply chain (118)
Tariffs (96)
The Weekly (82)
Vaccines (1083)
Venture capital (100)
Weight loss (439)
Women's health (109)
Worklife (19)
Date
Today (168)
Last 7 days (689)
Last 30 days (2860)
Last 365 days (30627)
2026 (7844)
2025 (30678)
2024 (35762)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54792)
2019 (47405)
2018 (35773)
2017 (33137)
2016 (32663)
2015 (38616)
2014 (32520)
2013 (27631)
2012 (29730)
2011 (30487)
2010 (28497)
Location
Africa (802)
Alabama (88)
Alaska (7)
Arizona (335)
Arkansas (15)
Asia (42378)
Australia (6786)
California (12272)
Canada (3516)
China (1256)
Colorado (522)
Connecticut (521)
Delaware (367)
Europe (91053)
Florida (1854)
Georgia (392)
Hawaii (3)
Idaho (61)
Illinois (973)
India (81)
Indiana (565)
Iowa (22)
Japan (496)
Kansas (130)
Kentucky (44)
Louisiana (40)
Maine (73)
Maryland (1489)
Massachusetts (8799)
Michigan (347)
Minnesota (676)
Mississippi (6)
Missouri (137)
Montana (33)
Nebraska (29)
Nevada (136)
New Hampshire (82)
New Jersey (3275)
New Mexico (29)
New York (3236)
North Carolina (1571)
North Dakota (8)
Northern California (6060)
Ohio (363)
Oklahoma (23)
Oregon (46)
Pennsylvania (2486)
Puerto Rico (25)
Rhode Island (50)
South America (1178)
South Carolina (75)
South Dakota (1)
Southern California (4818)
Tennessee (198)
Texas (1926)
United States (43565)
Utah (368)
Vermont (1)
Virginia (307)
Washington D.C. (80)
Washington State (988)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
746,202 Results for "xenon pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Xenon To Seek Approval of First-in-Class Epilepsy Drug After Exceeding Phase 3 Expectations
Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7%. Xenon Pharmaceuticals believes this is the highest such efficacy “observed in a pivotal epilepsy study,” CEO Ian Mortimer said Monday.
March 9, 2026
·
3 min read
·
Heather McKenzie
Press Releases
Xenon Pharmaceuticals Announces Proposed Public Offering - March 9, 2026
March 9, 2026
·
4 min read
Press Releases
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
March 11, 2026
·
5 min read
Press Releases
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
March 13, 2026
·
3 min read
Press Releases
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 16, 2026
January 19, 2026
·
2 min read
Press Releases
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
February 27, 2026
·
12 min read
Press Releases
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
March 9, 2026
·
1 min read
Press Releases
Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)
March 9, 2026
·
11 min read
Press Releases
Xenon to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
·
4 min read
Press Releases
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 4, 2025
December 5, 2025
·
2 min read
1 of 74,621
Next
